

Veolia North America - Industrial Business Regulatory Update - June 2019

ENVIRONMENTAL UPDATES

- A. EPA Final FY 2020-2021 Office of Enforcement and Compliance Assurance (OECA) National Program Guidance

TRANSPORTATION UPDATES

No Transportation Updates for the Month of June

HEALTH & SAFETY UPDATES

No Health and Safety Updates for the Month of June

MISCELLANEOUS UPDATES

- B. DOJ/DEA Schedules of Controlled Substances: Placement of Brexanolone in Schedule IV; Interim Final Rule
- C. DOJ/DEA Schedules of Controlled Substances: Placement of Solriamfetol in Schedule IV; Interim Final Rule

A. EPA Final FY 2020-2021 Office of Enforcement and Compliance Assurance (OECA) National Program Guidance

Agency

Environmental Protection Agency (EPA)

Dates

Published Date: June 7, 2019

Summary

On June 7, 2019, EPA's Office of Enforcement and Compliance Assurance (OECA) published their National Program Guidance for Fiscal Years 2020-2021. In an effort to focus its compliance and enforcement efforts on the most serious environmental and public health issues, EPA has selected six National Compliance Initiatives (NCIs) for the 2020-2021 cycle. The six NCIs are:

1. Reducing Excess Emissions of Harmful Pollutants from Stationary Sources;
2. Reducing Hazardous Emissions from Hazardous Waste Facilities;
3. Stopping Aftermarket Defeat Devices for Vehicles and Engines;
4. Reducing "Significant Non-Compliance" with National Pollution Discharge Elimination System (NPDES) Permits
5. Reducing Non-Compliance with Drinking Water Standards at Community Water Systems; and
6. Reducing the Risks of Accidental Releases at Industrial and Chemical Facilities

Reference/Link

Publication Number: 300B199001

The link below will allow you to view/print this document.

<https://www.epa.gov/sites/production/files/2019-06/documents/fy-20-21-oeca-np-guidance.pdf>

B. DOJ/DEA Schedules of Controlled Substances: Placement of Brexanolone in Schedule IV; Interim Final Rule

Agency

Department of Justice; Drug Enforcement Agency (DEA)

Dates

Published Date: June 17, 2019

Effective Date: June 17, 2019

Summary

On June 17, 2019, the Department of Justice, Drug Enforcement Administration (DEA) published an interim final rule placing brexanolone (3 α -hydroxy-5 α -pregnan-20-one; allopregnanolone; Zulresso) its salts, isomers, and salts of isomers into Schedule IV of the Controlled Substances Act (CSA). Brexanolone is a new nonsteroidal inhibitory drug with central nervous system depressant properties that is used to treat postpartum depression in adult women. After reviewing the scientific and medical documentation and the completion of the eight-factor review procedure DEA has determined that brexanolone meets the criteria for placement in Schedule IV of the CSA.

Reference/Link

Docket No. DEA-503; FR Vol 84, No. 116, 6/17/19, 27938

The link below will allow you to view/print this interim final rule..

<https://www.govinfo.gov/content/pkg/FR-2019-06-17/pdf/2019-12721.pdf>

C. **DOJ/DEA Schedules of Controlled Substances: Placement of Solriamfetol in Schedule IV; Interim Final Rule**

Agency

Department of Justice; Drug Enforcement Agency (DEA)

Dates

Published Date: June 17, 2019

Effective Date: June 17, 2019

Summary

On June 17, 2019, the Department of Justice, Drug Enforcement Agency (DEA) published an interim final rule placing solriamfetol ((R)-2-amino-3-phenylpropyl carbamate hydrochloride) into schedule IV of the Controlled Substances Act (CSA). Solriamfetol (SUNOSI) is a new drug used to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). After reviewing the scientific and medical documents and performing the eight-factor analysis of the abuse potential of solriamfetol, DEA has determined that solriamfetol meets the requirements for placement into Schedule IV of the CSA.

Reference/Link

The link below will allow you to view/print this interim final rule.

<https://www.govinfo.gov/content/pkg/FR-2019-06-17/pdf/2019-12723.pdf>